Skip to content

The clinical evaluation of Acupuncture for cognitive impairment in Parkinson's disease:Study Protocol for a Prospective Randomized Controlled Trial

The clinical evaluation of Acupuncture for cognitive impairment in Parkinson's disease:Study Protocol for a Prospective Randomized Controlled Trial

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400087389
Enrollment
Unknown
Registered
2024-07-26
Start date
2024-08-01
Completion date
Unknown
Last updated
2024-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cognitive impairment in Parkinson's disease

Interventions

Treatment Group:Acupuncture was performed on the basis of the subjects' regular intake of Parkinson's disease-based medications, and the acupuncture treatment was performed by a physician specializing
Control Group:Acupuncture treatment is performed on the basis of the subject taking Parkinson's drugs regularly and is administered by a physician specializing in acupuncture. Needle selection: Park s

Sponsors

Beijing Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 85 Years

Inclusion criteria

Inclusion criteria: (1) the diagnostic criteria of Parkinson's disease (2016); (2) aged between 30 and 85 years; (3) MoCA score <26 points; (4) PDCRS score<80.5 points. (The score between 73.5-80.5 was diagnosed as Parkinson's mild cognitive impairment (PD-MCI), and the score between 73.5 or less was diagnosed as Parkinson's dementia (PDD)); (5) Able to cooperate and complete the relevant evaluation and treatment, and the patients did not take oral cognition-related medication related to improving cognitive function in the 30 days before entering this study; (6) Signed the informed consent.

Exclusion criteria

Exclusion criteria: (1) patients with Parkinsonian superimposed syndrome or secondary Parkinsonian syndrome caused by traumatic brain injury, epilepsy, and other primary etiologies where cognitive impairment exists; (2) patients with severe cardiac, hepatic, or renal disease as well as deafness, epilepsy, or blindness; (3) patients with combined severe depression, anxiety, and schizophrenia; (4) patients with conscious or mental disorders who cannot cooperate with the treatment; (5) patients who cannot receive acupuncture or cognitive function training treatment.

Design outcomes

Secondary

MeasureTime frame
Electroencephalogram (EEG);a-synuclein(a-Syn);Complete Blood Count;Lipid Profile;T&T Olfactometry;Parkinson’s Disease Questionnaire - 39(PDQ-39);

Primary

MeasureTime frame
Montreal Cognitive Assessment(MoCA);Parkinson's disease-cognitive rating scale(PD-CRS);

Countries

CHINA

Contacts

Public ContactCui Yingxue

Beijing Hospital of Traditional Chinese Medicine

yingxuecui@163.com+86 134 8870 7925

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026